# MECHANISMS OF MULTI DRUG RESISTANCE IN MICROORGANISMS AND CANCER CELLS: AN OVERVIEW

**N T Pramathesh Mishra[1], Lucy Mohapatra[1]*, Zeashan Hussain[2]**

**Abstract**

Multidrug resistance (MDR) is a major challenge in the treatment of infectious diseases caused by microorganisms and cancer. MDR can occur through various mechanisms including efflux pumps, target modification, and impermeable barriers, among others. In microorganisms, MDR is a significant public health concern due to the emergence of antibiotic-resistant strains. In cancer cells, MDR is a major cause of treatment failure and disease progression. Understanding the mechanisms of MDR in microorganisms and cancer cells is crucial for the development of effective treatment strategies. In this overview, we discuss the various mechanisms of MDR, including genetic mutations, selection pressure, and horizontal gene transfer, and explore potential treatment options, such as combination therapy, targeted therapy, immunotherapy, and nanoparticle-based drug delivery. While the development of MDR is a complex and multifaceted problem, continued research and innovation in drug development and treatment strategies hold promise for overcoming this challenge.

**Keywords:** Multi Drug Resistance (MDR), DNA Repair, Cancer Cells, Microorganisms, Enzymatic Degradation

[1*]Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Sector 125, Noida, 201313, India
[2]Mahatma Gandhi Institute of Pharmacy, Junabganj, Lucknow, Uttar Pradesh, 227101, India

***Corresponding Author**: Lucy Mohapatra
[*]Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Sector 125, Noida, 201313, India
Email: lmohapatra@lko.amity.edu , dr.lucymohapatra@gmail.com

**DOI:** - 10.48047/ecb/2023.12.si5a.056

## INTRODUCTION

Drug resistance refers to the ability of microorganisms or cancer cells to survive exposure to drugs that would normally kill or inhibit their growth. It is a major challenge in the treatment of infectious diseases and cancer, as it can lead to treatment failure and disease recurrence. Drug resistance can arise through various mechanisms, including genetic mutations, selection pressure, and horizontal gene transfer. Understanding the mechanisms of drug resistance is essential for the development of effective treatment strategies and the prevention of drug resistance in the first place.[1]

**Types of drug resistance** [2]

There are several types of drug resistance, which can be broadly categorized as follows:

1. **Intrinsic resistance**: This type of resistance is present in microorganisms or cancer cells from the outset and is usually a result of innate biological features that prevent the drug from working effectively.
2. **Acquired resistance**: This type of resistance develops over time in response to exposure to a drug. It can arise through genetic mutations or changes in gene expression, and can be further divided into the following categories:

a. **Single-drug resistance**: This occurs when microorganisms or cancer cells develop resistance to a specific drug.
b. **Multi-drug resistance**: This occurs when microorganisms or cancer cells become resistant to multiple drugs that are structurally and functionally unrelated.
c. **Cross-resistance**: This occurs when resistance to one drug confers resistance to another drug that is structurally or functionally similar.

3. **Secondary resistance**: This type of resistance arises after a period of successful treatment with a drug. It occurs when microorganisms or cancer cells develop new mechanisms of resistance in response to prolonged exposure to the drug.

### 1. Intrinsic resistance

Intrinsic resistance refers to the inherent ability of microorganisms or cancer cells to resist the effects of a drug due to their natural biological characteristics. Intrinsic resistance can arise due to several factors, such as the presence of drug efflux pumps that actively pump out drugs from the cell, impermeable barriers that prevent drugs from entering the cell, or structural differences in drug targets that make them less susceptible to the drug's action. For example, many Gram-negative bacteria are intrinsically resistant to certain antibiotics, such as vancomycin, due to the presence of an outer membrane that prevents the drug from reaching its target. Similarly, some cancer cells are intrinsically resistant to chemotherapy drugs due to their inherent ability to repair DNA damage, which is the mechanism by which many chemotherapy drugs kill cancer cells.[2, 3]

Intrinsic resistance can be a major challenge in the treatment of microorganisms and cancer, as it limits the effectiveness of many drugs. Developing drugs that can overcome intrinsic resistance is a major area of research and involves understanding the mechanisms underlying intrinsic resistance and developing drugs that can circumvent these mechanisms. [4]

### 2. Acquired resistance

Acquired resistance refers to the ability of microorganisms or cancer cells to develop resistance to a drug after exposure to that drug. This can occur through several mechanisms, including genetic mutations, changes in gene expression, and horizontal gene transfer. Genetic mutations can alter the target of the drug or the metabolic pathway of the microorganism or cancer cell, rendering the drug less effective or ineffective. Changes in gene expression can lead to the overproduction of drug efflux pumps or other proteins that can inactivate or degrade the drug. Horizontal gene transfer, such as through plasmids or transposons, can transfer genes encoding resistance mechanisms between different microorganisms or cancer cells. [5]

Acquired resistance can be further categorized into single-drug resistance, multi-drug resistance, and cross-resistance. Single-drug resistance refers to resistance to a single drug, while multi-drug resistance refers to resistance to multiple drugs. Cross-resistance occurs when resistance to one drug confers resistance to other drugs that are structurally or functionally similar. Acquired resistance is a major challenge in the treatment of microorganisms and cancer, as it can lead to treatment failure and disease recurrence. Developing strategies to prevent or overcome acquired resistance is an important area of research and involves understanding the mechanisms underlying acquired resistance and developing drugs that can circumvent or target these mechanisms. [6]

#### a. Single-drug resistance

Single-drug resistance refers to the ability of microorganisms or cancer cells to resist the effects of a specific drug. This can occur through several mechanisms, including genetic mutations that alter

the target of the drug or the metabolic pathway of the microorganism or cancer cell, changes in gene expression that lead to the overproduction of drug efflux pumps or other proteins that can inactivate or degrade the drug, or changes in the cell membrane that prevent the drug from entering the cell. Single-drug resistance can arise through selective pressure, which occurs when exposure to a drug causes the selection of microorganisms or cancer cells that are naturally resistant or have acquired resistance mechanisms. This can occur when a patient is not fully compliant with treatment or when the dosage or duration of treatment is not sufficient to eliminate all the microorganisms or cancer cells. [6, 7]

Single-drug resistance is a significant problem in the treatment of infectious diseases and cancer, as it can limit the effectiveness of many drugs. Developing strategies to prevent or overcome single-drug resistance is an important area of research and involves understanding the mechanisms underlying resistance and developing drugs that can circumvent or target these mechanisms. [8]

**b. Multi-drug resistance**

Multi-drug resistance (MDR) refers to the ability of microorganisms or cancer cells to resist the effects of multiple drugs that are structurally and functionally unrelated. MDR can occur through various mechanisms, including the overproduction of drug efflux pumps, changes in the cell membrane that prevent drugs from entering the cell, and the presence of enzymes that can inactivate or degrade multiple drugs. [9]

MDR can arise through selective pressure, in which exposure to one drug leads to the selection of microorganisms or cancer cells that are also resistant to other drugs. It can also arise through the horizontal transfer of resistance genes between microorganisms or cancer cells. MDR is a major challenge in the treatment of infectious diseases and cancer, as it limits the number of effective treatment options and can lead to treatment failure and disease recurrence. Developing strategies to prevent or overcome MDR is an important area of research and involves understanding the mechanisms underlying resistance and developing drugs that can circumvent or target these mechanisms. Combination therapies that use multiple drugs with different mechanisms of action can also be effective in treating MDR infections or cancers.[10]

**c. Cross-resistance:**

Cross-resistance occurs when resistance to one drug confers resistance to other drugs that are structurally or functionally similar. This can occur when the resistance mechanism is common to multiple drugs or when the resistance mechanism confers a more general survival advantage to the microorganism or cancer cell. Cross-resistance can arise through selective pressure, in which exposure to one drug leads to the selection of microorganisms or cancer cells that are also resistant to structurally or functionally similar drugs. It can also arise through the horizontal transfer of resistance genes between microorganisms or cancer cells.[11]

Cross-resistance is a significant problem in the treatment of infectious diseases and cancer, as it can limit the number of effective treatment options and lead to treatment failure and disease recurrence. Developing strategies to prevent or overcome cross-resistance is an important area of research and involves understanding the mechanisms underlying resistance and developing drugs that can circumvent or target these mechanisms. Combination therapies that use multiple drugs with different mechanisms of action can also be effective in treating cross-resistant infections or cancers. [11,12]

**3. Secondary resistance**

Secondary resistance, also known as acquired resistance, refers to the development of resistance to a drug after initial treatment has been successful. This can occur through several mechanisms, including genetic mutations, changes in gene expression, and horizontal gene transfer. Secondary resistance can arise when the initial treatment kills off most of the susceptible microorganisms or cancer cells, leaving behind a population of resistant variants that continue to grow and divide. Alternatively, secondary resistance can arise through the selection of resistant variants during initial treatment, which then become the dominant population over time.

Secondary resistance is a significant problem in the treatment of infectious diseases and cancer, as it can lead to treatment failure and disease recurrence. Developing strategies to prevent or overcome secondary resistance is an important area of research and involves understanding the mechanisms underlying resistance and developing drugs that can circumvent or target these mechanisms. Combination therapies that use multiple drugs with different mechanisms of action can also be effective in preventing or delaying the development of secondary resistance.[13]

**Mechanisms of drug resistance in microorganisms [14]**

Microorganisms can develop resistance to drugs through various mechanisms, including:

1. **Mutation:** Microorganisms can develop resistance through genetic mutations that alter the target of the drug, the metabolic pathway of the microorganism, or the structure of the drug binding site.
2. **Efflux pumps:** Microorganisms can develop resistance by overproducing drug efflux pumps, which are transporters that pump drugs out of the cell, thereby reducing the concentration of the drug inside the cell.
3. **Biofilm formation**: Microorganisms can develop resistance by forming biofilms, which are communities of microorganisms that are protected by a matrix of extracellular substances. Biofilms can prevent drugs from penetrating the cell and reaching their targets.
4. **Enzymatic degradation**: Microorganisms can develop resistance by producing enzymes that can inactivate or degrade the drug, rendering it ineffective.
5. **Altered metabolic pathways**: Microorganisms can develop resistance by altering their metabolic pathways to bypass the drug target or the pathway that leads to the drug's activation.
6. **Target modification**: Microorganisms can develop resistance by modifying the target of the drug, such as an enzyme or a receptor, so that the drug is no longer able to bind and inhibit its activity.
7. **Horizontal gene transfer**: Microorganisms can acquire resistance genes through horizontal gene transfer, which occurs when genetic material is transferred between organisms by mechanisms such as conjugation, transduction, or transformation.




**Figure 1: Illustration of mechanisms of chemotherapeutic drug resistance associated with cancer cells.**

**A. Efflux pumps**

Efflux pumps are transporters that are present in the cell membrane of microorganisms and cancer cells. They work by actively pumping drugs out of the cell, thereby reducing the concentration of the drug inside the cell and making the microorganism or cancer cell resistant to the drug. Efflux pumps are a common mechanism of drug resistance in both microorganisms and cancer cells. Efflux pumps can be specific to a single drug or can pump out a broad range of structurally unrelated drugs. These pumps are classified into several families, including the ATP-binding cassette (ABC) transporters, the major facilitator superfamily (MFS) transporters, and the resistance-nodulation-division (RND) family transporters.[15]

ABC transporters are energy-dependent efflux pumps that are present in many microorganisms and cancer cells. These pumps are involved in the transport of a wide range of compounds, including drugs, nutrients, and toxins. MFS transporters are another class of efflux pumps that are widely distributed in microorganisms and cancer cells. They are responsible for the efflux of many structurally diverse compounds, including drugs, organic acids, and antibiotics. The RND family of efflux pumps is found in Gram-negative bacteria and are involved in the efflux of a broad range of drugs, including antibiotics, detergents, and heavy metals. Efflux pumps play a critical role in the development of drug resistance and are a significant barrier to the treatment of infectious diseases and cancer. Developing drugs that can bypass or inhibit efflux pumps is an active area of research, and combination therapies that use drugs that are not substrates of efflux pumps can be effective in treating drug-resistant infections and cancers. [14, 15]

**B. Target modification**

Target modification is a mechanism of drug resistance that occurs when microorganisms or cancer cells modify the target of the drug, such as

an enzyme or a receptor, so that the drug is no longer able to bind and inhibit its activity. This can occur through several mechanisms, including genetic mutations, changes in gene expression, or post-translational modifications. For example, bacteria can develop resistance to antibiotics that target the bacterial ribosome, which is responsible for protein synthesis, through genetic mutations that alter the structure of the ribosome so that the antibiotic can no longer bind and inhibit its activity. Similarly, cancer cells can develop resistance to chemotherapy drugs that target specific receptors, such as the epidermal growth factor receptor (EGFR), through mutations that alter the receptor structure or expression levels.[16]

Target modification can be a primary or secondary mechanism of drug resistance, depending on whether it arises before or after exposure to the drug. Primary resistance occurs when a microorganism or cancer cell is naturally resistant to a drug due to pre-existing genetic mutations or alterations in gene expression. Secondary resistance occurs when a microorganism or cancer cell acquires resistance to a drug after exposure to the drug, typically through the selection of resistant variants that have developed genetic mutations or changes in gene expression. Developing drugs that can bypass or target alternative pathways in microorganisms or cancer cells is a strategy to overcome target modification-mediated drug resistance. Additionally, combination therapies that use multiple drugs with different mechanisms of action can be effective in preventing or delaying the development of secondary resistance through target modification. [16,17]

**c. Impermeable barriers**

Impermeable barriers are a mechanism of drug resistance in microorganisms that occurs when the cell membrane becomes less permeable to drugs, preventing them from entering the cell and reaching their target. This can occur through a variety of mechanisms, including changes in the cell membrane composition or structure, decreased expression of porins, and the formation of biofilms. In gram-negative bacteria, porins are proteins that form channels in the outer membrane, allowing nutrients and small molecules, such as antibiotics, to enter the cell. Decreased expression of porins or mutations in porin genes can lead to decreased permeability of the outer membrane, making it more difficult for drugs to enter the cell.

In addition, some microorganisms can form biofilms, which are complex communities of microorganisms that are protected by a matrix of extracellular polymeric substances. Biofilms can act as a physical barrier to drugs, preventing them from penetrating the biofilm and reaching the microorganisms inside.

Impermeable barriers can be a primary or secondary mechanism of drug resistance, depending on whether they arise before or after exposure to the drug. Primary resistance occurs when a microorganism is naturally impermeable to a drug due to pre-existing changes in the cell membrane composition or structure. Secondary resistance occurs when a microorganism acquires resistance to a drug after exposure to the drug, typically through the selection of resistant variants that have developed changes in the cell membrane composition or structure. To overcome impermeable barrier-mediated drug resistance, drug developers can design drugs that are more effective at penetrating the cell membrane or that can exploit alternative pathways for entry into the cell. Combination therapies that use drugs that can overcome impermeable barriers along with drugs that target other mechanisms of resistance can also be effective in treating drug-resistant infections.[17]

**Mechanisms of drug resistance in cancer cells [18]**

Cancer cells can develop resistance to chemotherapy and targeted therapies through several mechanisms, including:

1. **Altered drug targets**: Cancer cells can develop mutations that alter the drug target, such as a receptor or an enzyme, reducing the drug's ability to bind and inhibit its activity. For example, mutations in the epidermal growth factor receptor (EGFR) can cause resistance to EGFR-targeted therapies.
2. **Drug efflux pumps**: Like microorganisms, cancer cells can overexpress efflux pumps, such as P-glycoprotein (P-gp), which pump drugs out of the cell, reducing drug concentrations and efficacy.
3. **Altered drug metabolism**: Cancer cells can develop changes in drug metabolism pathways, such as overexpression of drug-metabolizing enzymes or downregulation of drug-activating enzymes, reducing drug concentrations and efficacy.
4. **DNA repair mechanisms**: Cancer cells can develop enhanced DNA repair mechanisms, which can reduce the effectiveness of DNA-damaging chemotherapy drugs.
5. **Apoptosis resistance**: Cancer cells can develop resistance to programmed cell death, or apoptosis, which is induced by many

chemotherapy drugs. This can occur through several mechanisms, including mutations in pro-apoptotic proteins, overexpression of anti-apoptotic proteins, and activation of survival signaling pathways.

6. **Tumor microenvironment**: The tumor microenvironment, which includes factors such as hypoxia, immune cells, and extracellular matrix components, can promote drug resistance by reducing drug delivery to the tumor, inducing drug efflux pumps, and promoting cancer cell survival.

These mechanisms can occur independently or in combination with each other, leading to multi-drug resistance in cancer cells. To overcome drug resistance in cancer cells, combination therapies that target multiple mechanisms of resistance, or that target both the cancer cells and the tumor microenvironment, can be effective. Additionally, developing drugs that target new mechanisms of resistance or that can overcome existing resistance mechanisms can improve treatment outcomes.[19]

**A. Overexpression of drug efflux pumps**

Overexpression of drug efflux pumps is a common mechanism of drug resistance in both microorganisms and cancer cells. These pumps are membrane-bound transporters that can actively pump drugs out of the cell, reducing their effective concentration and rendering them ineffective.

In microorganisms, efflux pumps can be naturally present or can be acquired through mutations or the acquisition of plasmids carrying resistance genes. Some examples of efflux pumps in microorganisms include the AcrAB-TolC system in Escherichia coli and the MexAB-OprM system in Pseudomonas aeruginosa. [20]

In cancer cells, the overexpression of efflux pumps such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-associated protein (MRP) can lead to resistance to a broad range of chemotherapeutic drugs. P-gp is the most extensively studied efflux pump in cancer cells and is commonly overexpressed in many types of cancer, including breast, colon, and lung cancer. [21]

Overexpression of drug efflux pumps can be a primary or secondary mechanism of drug resistance, depending on whether it arises before or after exposure to the drug. Primary resistance occurs when the efflux pump is overexpressed in the absence of drug exposure, while secondary resistance occurs when the efflux pump is upregulated after exposure to the drug.[ 22]

To overcome drug resistance mediated by overexpression of efflux pumps, drug developers can design drugs that are less susceptible to efflux, such as by modifying the drug's structure to reduce its affinity for the efflux pump. Combination therapies that use drugs that are not substrates of the efflux pump along with drugs that target other mechanisms of resistance can also be effective in treating drug-resistant infections or cancers. Additionally, inhibitors of efflux pumps can be used to increase the concentration of drugs in cells, although the use of these inhibitors is currently limited due to toxicity concerns. [22, 23]

**B. Altered drug targets.**

Altered drug targets are another mechanism of drug resistance that can occur in both microorganisms and cancer cells. Alterations in drug targets can occur through genetic mutations, epigenetic modifications, or changes in the expression level of the target protein. In microorganisms, alterations in the drug target can occur through genetic mutations or horizontal gene transfer. For example, mutations in the beta-lactamase enzyme in bacteria can result in resistance to beta-lactam antibiotics such as penicillin. Mutations in the target site of fluoroquinolone antibiotics in bacteria can also lead to resistance to these drugs. [24]

In cancer cells, alterations in the drug target can occur through genetic mutations, epigenetic modifications, or changes in the expression level of the target protein. For example, mutations in the epidermal growth factor receptor (EGFR) in non-small cell lung cancer can result in resistance to EGFR inhibitors such as gefitinib and erlotinib. Additionally, changes in the expression level of the target protein can also contribute to resistance. For instance, downregulation of the target protein HER2 in breast cancer can result in resistance to the HER2-targeted therapy trastuzumab.[25]

To overcome resistance caused by altered drug targets, drug developers can design drugs that target multiple variants of the target protein or that target alternative pathways that bypass the mutated target. Combination therapies that use drugs that target the mutated protein along with drugs that target other mechanisms of resistance can also be effective in treating drug-resistant infections or cancers. Additionally, genetic testing to identify mutations in the drug target can help guide treatment decisions and the selection of appropriate drugs. [26]

**C. Impaired apoptosis**

Apoptosis, also known as programmed cell death, is a natural process by which cells undergo self-destruction to maintain tissue homeostasis and remove damaged or abnormal cells. Impaired apoptosis is a mechanism of drug resistance that can occur in cancer cells.[27]

Many chemotherapeutic drugs induce apoptosis in cancer cells as a mechanism of killing. However, cancer cells can develop resistance to apoptosis by altering the expression of proteins involved in the apoptotic pathway, such as caspases, Bcl-2 family members, and the tumor suppressor p53. For example, overexpression of anti-apoptotic Bcl-2 family members can block apoptosis by preventing the release of mitochondrial cytochrome c, which is necessary for the activation of caspases. In addition, mutations, or loss of function of the tumor suppressor p53 can impair apoptosis by reducing the expression of pro-apoptotic proteins or increasing the expression of anti-apoptotic proteins.[28]

To overcome resistance caused by impaired apoptosis, drug developers can design drugs that bypass the apoptotic pathway, such as drugs that induce necrosis or autophagy in cancer cells. Combination therapies that use drugs that target impaired apoptosis along with drugs that target other mechanisms of resistance can also be effective in treating drug-resistant cancers. Additionally, genetic testing to identify mutations in the apoptotic pathway can help guide treatment decisions and the selection of appropriate drugs. [29]

**D. Epigenetic changes**

Epigenetic changes are modifications to the structure of DNA and its associated proteins that can influence gene expression without changing the underlying DNA sequence. These changes can be heritable and can contribute to the development of drug resistance in both microorganisms and cancer cells. [29, 30]

In microorganisms, epigenetic changes can result in the upregulation or downregulation of genes involved in drug resistance mechanisms. For example, the upregulation of genes involved in efflux pumps or the downregulation of genes involved in drug targets can contribute to antibiotic resistance. In addition, epigenetic changes can also affect the expression of genes involved in bacterial biofilm formation, which can lead to increased resistance to antibiotics. [31]

In cancer cells, epigenetic changes can result in the silencing of tumor suppressor genes or the activation of oncogenes, leading to uncontrolled cell growth and resistance to chemotherapy. For example, DNA methylation, histone modifications, and non-coding RNAs have been implicated in the development of drug resistance in cancer cells. In particular, the silencing of tumor suppressor genes by DNA hypermethylation and the activation of oncogenes by histone modifications have been shown to contribute to resistance to chemotherapy in various cancer types.[32]

To overcome resistance caused by epigenetic changes, drug developers can design drugs that target epigenetic regulators, such as DNA methyltransferases, histone deacetylases, and histone methyltransferases. Combination therapies that use epigenetic drugs along with chemotherapy or other targeted therapies can also be effective in treating drug-resistant cancers. Additionally, biomarker testing to identify epigenetic changes can help guide treatment decisions and the selection of appropriate drugs.[33]

**Common themes in drug resistance** [34]

Although the mechanisms of drug resistance in microorganisms and cancer cells differ, there are some common themes that underlie drug resistance in both contexts. These include:

1. **Genetic diversity**: Microorganisms and cancer cells can acquire mutations or undergo genetic changes that lead to the development of drug resistance. Genetic diversity can allow some cells to survive and proliferate in the presence of drugs, leading to the development of drug-resistant populations.
2. **Selective pressure:** The use of drugs to treat infections or cancer can create selective pressure that favors the survival and growth of drug-resistant microorganisms or cancer cells. The more drugs are used, the more selective pressure is applied, which can lead to the development of more resistant strains.
3. **Adaptation**: Microorganisms and cancer cells can adapt to their environment, including the presence of drugs, by changing their behavior or physiological properties. For example, bacteria can form biofilms that provide a physical barrier to drugs, while cancer cells can undergo metabolic changes that make them less sensitive to chemotherapy.
4. **Resistance mechanisms:** Both microorganisms and cancer cells can develop mechanisms to actively resist the effects of drugs. These mechanisms can include the upregulation of

efflux pumps to expel drugs, the alteration of drug targets to make them less susceptible to drugs, or the activation of survival pathways that counteract the effects of drugs.

5. **Persistence**: Some microorganisms and cancer cells can enter a state of persistence or dormancy that makes them less susceptible to drugs. In this state, the cells can survive for long periods of time without dividing, making them difficult to eliminate with standard drug therapies.

**Prevention of drug penetration**

One of the mechanisms of drug resistance in microorganisms and cancer cells is the prevention of drug penetration. This can be achieved through various ways, such as the formation of impermeable barriers, which can prevent the drugs from entering the cells. For instance, in Gram-negative bacteria, the outer membrane acts as an impermeable barrier to many antibiotics, including beta-lactams. The outer membrane is made up of lipopolysaccharides and proteins, which can act as a barrier and prevent the drugs from entering the cell. Some bacteria can also produce a capsule or slime layer, which can prevent drugs from reaching the bacterial cell surface. [35]

Similarly, cancer cells can develop mechanisms to prevent drug penetration. For example, the extracellular matrix (ECM) can act as a barrier to drugs, preventing them from reaching cancer cells. The ECM is a complex network of proteins and sugars that surrounds cells, and it can affect drug penetration and efficacy. To overcome this mechanism of drug resistance, researchers are developing strategies to enhance drug penetration into cells. For instance, nanoparticles can be designed to carry drugs across the cell membrane and into the cytoplasm of cells. Similarly, researchers are developing drugs that can disrupt the ECM and improve drug penetration into tumors. These strategies hold promise for improving the efficacy of chemotherapy drugs and overcoming drug resistance in microorganisms and cancer cells.
[36]




**Fig 2: Prevention of Drug Penetrations:** Genome Editing, Characterizing Specific Barriers To Reaching Target Issues, Modulating Immune System and Response, Determining Pharmacokinetics Altered by Disease States

**Genetic mutations**

Genetic mutations are alterations in the DNA sequence that can lead to the development of drug resistance in microorganisms and cancer cells. Mutations can arise spontaneously or can be induced by environmental factors, such as exposure to drugs or radiation. [37]

In microorganisms, genetic mutations can result in changes to the structure or function of proteins involved in drug targets or drug efflux pumps. These changes can make the microorganisms less susceptible to the effects of drugs, leading to the development of drug resistance. For example, mutations in the bacterial gene gyrA can lead to resistance to fluoroquinolone antibiotics, while mutations in the gene rpoB can lead to resistance to rifampin.[38]

In cancer cells, genetic mutations can also result in changes to proteins involved in drug targets or DNA repair mechanisms. Mutations can lead to alterations in the structure or function of these proteins, making the cancer cells less susceptible to the effects of chemotherapy drugs. For example, mutations in the gene BRCA1 can lead to resistance to DNA-damaging agents such as cisplatin or PARP inhibitors. [39]

To overcome resistance caused by genetic mutations, drug developers can design drugs that target alternative pathways or mechanisms that are not affected by the mutations. Alternatively, combination therapies that target multiple pathways can be effective in treating drug-resistant microorganisms or cancer cells. Additionally, biomarker testing to identify specific mutations can help guide treatment decisions and the selection of appropriate drugs. [39, 40]

**Selection pressure**

Selection pressure is the process by which the use of drugs creates a selective environment that favors the survival and growth of microorganisms or cancer cells that are resistant to the drug. When a drug is used to treat an infection or cancer, it exerts pressure on the targeted cells to adapt and develop resistance mechanisms to survive and grow in the presence of the drug. In the case of microorganisms, the use of antibiotics creates selection pressure that favors the growth of antibiotic-resistant strains. As the antibiotic kills off susceptible bacteria, it creates an environment where the resistant bacteria can proliferate and take over the population. This can lead to the development of drug-resistant infections that are difficult to treat. [41]

Similarly, the use of chemotherapy drugs in cancer treatment can create selection pressure that favors the growth of cancer cells that are resistant to the drugs. As cancer cells undergo genetic mutations, those that have mutations that confer resistance to chemotherapy drugs will have a survival advantage over those that do not. Over time, the resistant cells can grow and spread, leading to a recurrence of cancer that is resistant to treatment.[42]

To mitigate the effects of selection pressure, drug developers can focus on designing drugs that are less likely to lead to the development of resistance, such as drugs that target multiple pathways or are less likely to induce genetic mutations. Additionally, treatment strategies that minimize the use of drugs, such as combination therapies, can reduce the selective pressure on microorganisms or cancer cells and prevent the development of resistance.[43]

**Horizontal gene transfer**

Horizontal gene transfer (HGT) is a process by which genetic material is transferred from one organism to another without reproduction. This process occurs commonly in microorganisms and can lead to the spread of resistance genes among bacterial populations. There are three main mechanisms of HGT: transformation, transduction, and conjugation. Transformation occurs when bacteria take up free DNA from the environment, while transduction involves the transfer of DNA from one bacterium to another by a bacteriophage (a virus that infects bacteria). Conjugation is the transfer of genetic material from one bacterium to another through direct cell-to-cell contact.[44]

HGT can contribute to the development and spread of drug resistance by allowing bacteria to acquire resistance genes from other bacteria that have developed resistance through mutations or exposure to drugs. For example, the spread of the mecA gene encoding resistance to methicillin in Staphylococcus aureus is largely due to horizontal transfer of the gene from other resistant strains.

In cancer cells, HGT can also play a role in the development of drug resistance. For example, cancer cells can acquire resistance to chemotherapy drugs through the transfer of resistance genes from other cells within the tumor or from adjacent tissues. [45]

To combat the spread of resistance genes through HGT, measures can be taken to limit the exposure of bacteria to antibiotics or chemotherapy drugs, such as through the appropriate use of antibiotics and combination therapies. Additionally, strategies such as the development of bacteriophages that target specific bacterial strains or the use of CRISPR-Cas systems that can selectively remove resistance genes from bacteria may be effective in reducing the spread of drug resistance through HGT.[46]

**Drug Resistance in Cancer : Role of Lnc RNA in reversing MDR**




**Fig 3:Drug Resistance In Cancer : Role of Lnc RNA in reversing MDR**

Long non-coding RNAs (lncRNAs) are a class of non-coding RNAs that are longer than 200 nucleotides and play crucial roles in gene regulation. Recently, there has been growing interest in the role of lncRNAs in drug resistance in cancer cells. Several studies have shown that dysregulated expression of lncRNAs can contribute to the development of multidrug resistance (MDR) in cancer cells. [47]

One of the ways lncRNAs can contribute to MDR is by regulating the expression of drug efflux pumps, which are membrane transporters that pump drugs out of cells, reducing their intracellular concentration. LncRNAs such as H19, HOTAIR, and MALAT1 have been shown to upregulate the expression of drug efflux pumps in cancer cells, leading to MDR. Similarly, lncRNAs such as GAS5, MEG3, and TUG1 have been shown to downregulate drug efflux pump expression, thereby reversing MDR.[48]

Another way lncRNAs can contribute to MDR is by regulating the expression of genes involved in apoptosis and cell survival. LncRNAs such as ANRIL, HOTAIR, and XIST have been shown to promote cancer cell survival and inhibit apoptosis, leading to MDR. Targeting lncRNAs has emerged as a promising strategy for overcoming MDR in cancer cells. Several studies have shown that inhibition of lncRNAs such as HOTAIR, MALAT1, and H19 can sensitize cancer cells to chemotherapy drugs and reverse MDR. Similarly, overexpression of lncRNAs such as GAS5, MEG3, and TUG1 can enhance chemotherapy drug efficacy and reverse MDR. lncRNAs play a critical role in the development of MDR in cancer cells by regulating the expression of drug efflux pumps, apoptosis, and cell survival genes. Targeting lncRNAs holds promise for overcoming MDR and improving the efficacy of chemotherapy drugs in the treatment of cancer.[48,49]

**Clinical implications**

The development and spread of drug resistance have significant clinical implications for the treatment of infections and cancer. When microorganisms or cancer cells become resistant to commonly used drugs, treatment options become limited, and more aggressive and costly treatments may be required. This can lead to longer hospital stays, increased healthcare costs, and a higher risk of treatment failure, relapse, or mortality.[ 50]

In the case of infections, drug-resistant microorganisms can cause severe and life-threatening illnesses that are difficult to treat. This can lead to longer hospital stays, more frequent use of antibiotics, and higher rates of morbidity and mortality. Drug-resistant infections are a growing public health concern and can have significant economic and social impacts on individuals and communities. In cancer treatment, the development of drug resistance can lead to treatment failure, disease progression, and decreased overall survival. When cancer cells become resistant to chemotherapy drugs, treatment options become limited, and the cancer may become more aggressive and difficult to control. This can lead to the need for more intensive and costly treatments, such as targeted therapies or immunotherapies, that may not be available to all patients.[51]

To address the clinical implications of drug resistance, efforts are being made to develop new drugs and treatment strategies that can overcome or prevent resistance. This includes the development of novel antibiotics and cancer therapies that target multiple pathways or use different mechanisms of action, as well as the use of combination therapies that can reduce the risk of resistance. Additionally,

efforts are being made to improve infection control measures in healthcare settings and to promote the appropriate use of antibiotics and other drugs to limit the development and spread of drug resistance. [52]

**Treatment options**

The treatment options for drug-resistant infections and cancer depend on the specific organism or cancer type and the nature of the resistance. In general, treatment options for drug-resistant infections may include the use of alternative antibiotics or combination therapies, as well as the use of higher doses or longer treatment durations. For some infections, surgical intervention may be necessary to remove infected tissue or implants. In cancer treatment, the management of drug resistance may involve the use of alternative chemotherapy drugs, targeted therapies, immunotherapies, or combination therapies. Targeted therapies are designed to specifically target cancer cells that have specific mutations or genetic changes, while immunotherapies aim to boost the immune system's ability to recognize and attack cancer cells. Combination therapies may include the use of multiple drugs that target different pathways or mechanisms to increase the effectiveness of treatment and reduce the risk of resistance. [52, 53]

In addition to these treatments, efforts are being made to develop new drugs and treatment strategies that can overcome or prevent drug resistance. This includes the development of new antibiotics and cancer therapies, as well as the use of combination therapies that can reduce the risk of resistance. It is important to note that the prevention of drug resistance is a critical component of effective treatment. This includes the appropriate use of antibiotics and other drugs, as well as the promotion of infection control measures and the responsible use of antimicrobials in healthcare settings. It is also important for patients to follow treatment plans as directed and to communicate any concerns or side effects with their healthcare providers.[54]

**How to overcome the multidrug resistance in cancer** [54,55,56]

1. **Combination therapy**: Using multiple drugs that target different mechanisms of resistance may be more effective than using a single drug. For example, combining chemotherapy with targeted therapy or immunotherapy may help to improve treatment outcomes.
2. **Targeted therapy**: Targeted therapy drugs are designed to specifically target cancer cells and spare healthy cells, reducing the risk of toxicity and side effects. Identifying and targeting specific mutations or molecular markers that are present in cancer cells may help to overcome drug resistance.
3. **Immunotherapy**: Immunotherapy drugs work by stimulating the body's immune system to recognize and attack cancer cells. Immunotherapy has shown promise in treating some types of cancer and may help to overcome drug resistance by targeting cancer cells in a different way than chemotherapy drugs.
4. **Overcoming the tumor microenvironment:** The tumor microenvironment can create a protective environment for cancer cells, making them resistant to treatment. Strategies to overcome the tumor microenvironment include targeting the immune system, reducing inflammation, and improving oxygenation.
5. **Nanoparticle-based drug delivery:** Nanoparticles can be used to deliver drugs directly to cancer cells, reducing the risk of toxicity and improving drug efficacy.
6. **Overcoming multidrug resistance genes:** Drugs that can inhibit the function of multidrug resistance genes may help to overcome drug resistance.
7. **Gene editing:** Gene editing technologies such as CRISPR-Cas9 may be used to edit cancer cells to make them more susceptible to treatment.

**Drug development**

The development of new drugs and treatment strategies is an important aspect of addressing drug resistance. In the case of antibiotics, drug development efforts are focused on identifying new compounds that are effective against drug-resistant microorganisms, as well as the development of alternative therapies such as bacteriophages or probiotics. In cancer treatment, drug development efforts are focused on the development of new targeted therapies and immunotherapies, as well as the identification of biomarkers that can help predict treatment response and identify patients who are more likely to develop drug resistance. [57]

The drug development process typically involves several stages, including target identification, drug discovery and optimization, preclinical testing, and clinical trials. During preclinical testing, the safety and efficacy of the drug are evaluated in animal models and in vitro studies. If the drug shows promise, it may move into clinical trials, which involve testing the drug in humans to evaluate its safety and effectiveness. Clinical trials are typically

conducted in several phases, with each phase involving a larger number of patients and more rigorous testing. If the drug is found to be safe and effective in clinical trials, it may be approved by regulatory agencies such as the FDA for use in patients. The drug development process is a lengthy and costly process that can take several years or even decades to complete. However, the development of new drugs and treatment strategies is critical for addressing drug resistance and improving patient outcomes.
[58,59]

**Future directions** [60, 61,62,63]

There are several promising areas of research and development that may help to address drug resistance in the future. Some of these areas include:

1. **Development of alternative therapies**: In addition to traditional antibiotics and chemotherapy drugs, there is growing interest in the development of alternative therapies such as bacteriophages, probiotics, and immunotherapies.
2. **Personalized medicine**: Personalized medicine involves tailoring treatment to the specific characteristics of an individual patient, such as their genetic makeup or disease stage. This approach may help to improve treatment outcomes and reduce the risk of drug resistance.
3. **Combination therapies**: Combination therapies that target multiple pathways or mechanisms may help to reduce the risk of drug resistance and improve treatment outcomes.
4. **Use of artificial intelligence**: Artificial intelligence and machine learning technologies can help to identify new drug targets and predict which patients may be more likely to develop drug resistance.
5. **Improved infection control measures**: Improved infection control measures, including better sanitation practices and the development of new disinfectants, may help to reduce the spread of drug-resistant infections in healthcare settings.
6. **Public education and awareness**: Public education and awareness campaigns can help to promote responsible use of antibiotics and other drugs, which can help to reduce the risk of drug resistance.

## CONCLUSION

Multidrug resistance (MDR) is a complex problem that presents a significant challenge in the treatment of infectious diseases caused by microorganisms and cancer. The emergence of antibiotic-resistant strains of microorganisms and drug-resistant cancer cells is a growing public health concern, highlighting the need for continued research and innovation in drug development and treatment strategies. Understanding the mechanisms of MDR, including efflux pumps, target modification, and impermeable barriers, among others, is crucial for the development of effective treatment strategies. While there is no one-size-fits-all solution to overcoming MDR, combination therapy, targeted therapy, immunotherapy, nanoparticle-based drug delivery, and gene editing are some of the promising approaches that are being explored. Continued research and collaboration among researchers, clinicians, and pharmaceutical companies are essential for overcoming the challenge of MDR and improving patient outcomes.

## REFERENCES

1. Nikaido, H., & Pages, J. M. (2012). Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiology Reviews, 36(2), 340–363.
2. Li, X. Z., Plésiat, P., & Nikaido, H. (2015). The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clinical Microbiology Reviews, 28(2), 337–418.
3. Gottesman, M. M., Fojo, T., & Bates, S. E. (2002). Multidrug resistance in cancer: Role of ATP-dependent transporters. Nature Reviews Cancer, 2(1), 48–58.
4. Fletcher, J. I., Haber, M., Henderson, M. J., & Norris, M. D. (2010). ABC transporters in cancer: More than just drug efflux pumps. Nature Reviews Cancer, 10(2), 147–156.
5. van der Heijden, J. W., Oerlemans, R., Tak, P. P., & Assaraf, Y. G. (2013). P-glycoprotein-mediated drug efflux as a concomitant resistance mechanism in chronic inflammation-driven cancer progression. Seminars in Cancer Biology, 23(4), 293–302.
6. Martinez, J. L. (2008). Antibiotics and antibiotic resistance genes in natural environments. Science, 321(5887), 365–367.
7. Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O., & Piddock, L. J. V. (2015). Molecular mechanisms of antibiotic resistance. Nature Reviews Microbiology, 13(1), 42–51.
8. Lu, J. J., Perng, R. P., & Lee, S. Y. (2013). Wan, Proliferation and migration of cancer cells in the context of chemotherapeutic agents. Chinese Journal of Cancer, 32(9), 421–433.
9. Siddik, Z. H. (2003). Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene, 22(47), 7265–7279.
10. Dean, M., & Annilo, T. (2005). Evolution of the ATP-binding cassette (ABC) transporter

superfamily in vertebrates. Annual Review of Genomics and Human Genetics, 6, 123–142.
11. Prasad, R., & Goffeau, A. (2012). Yeast ATP-binding cassette transporters conferring multidrug resistance. Annual Review of Microbiology, 66, 39–63.
12. Bay, D. C., Rommens, K. L., Turner, R. J., & Paterson, I. G. (2008). The Pseudomonas aeruginosa multidrug efflux regulators MexR, NalC and MexZ interact directly with one another and with transcriptional repressors of the dhaS operon. Journal of Biological Chemistry, 283(48), 32065–32073.
13. Long, T. E., & Williams, J. D. (2007). Antibacterial resistance: An emerging global public health risk. Journal of Pharmacy Practice, 20(1), 5–16.
14. Fajardo, A., Martínez-Martín, N., & Mercadillo, M. (2008). Antibiotics as signals that trigger specific bacterial responses. Current opinion in microbiology, 11(2), 161-167.
15. Liu, B., Liu, Y., Jin, J., Zhang, Q., Yang, K., Yang, L., ... & Han, X. (2019). Mechanisms of antibiotic resistance: clinical implications and programming strategies. Future microbiology, 14(13), 1123-1136.
16. Martínez, J. L. (2008). Antibiotics and antibiotic resistance genes in natural environments. Science, 321(5887), 365-367.
17. Nikaido, H. (2009). Multidrug resistance in bacteria. Annual review of biochemistry, 78, 119-146.
18. Piddock, L. J. (2006). Multidrug-resistance efflux pumps—not just for resistance. Nature Reviews Microbiology, 4(8), 629-636.
19. Poole, K. (2001). Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. Journal of molecular microbiology and biotechnology, 3(2), 255-264.
20. Rasko, D. A., & Sperandio, V. (2010). Anti-virulence strategies to combat bacteria-mediated disease. Nature Reviews Drug Discovery, 9(2), 117-128.
21. Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G., Edwards Jr, J. E., & International, A. S. F. F. (2004). Trends in antimicrobial drug development: implications for the future. Clinical infectious diseases, 38(9), 1279-1286.
22. Su, X. Z., & Chen, J. (2010). The emergence and evolution of malaria parasites resistant to chloroquine in China. Chinese medical journal, 123(4), 539-546.
23. Yeh, P., Tschumi, A. I., & Kishony, R. (2006). Functional classification of drugs by properties of their pairwise interactions. Nature Genetics, 38(4), 489-494. Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview. Cancers (Basel). 2014;6(3):1769-1792.
24. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714-726.
25. Blagosklonny MV. Targeting cancer cells by exploiting their resistance. Trends Mol Med. 2003;9(7):307-312.
26. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615-627.
27. Yap TA, Workman P. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu Rev Pharmacol Toxicol. 2012;52:549-573.
28. Zhou W, Sun M, Li G, et al. From next-generation sequencing to nanopore sequencing technology: paving the way to personalized genomic medicine. Expert Rev Med Devices. 2017;14(5):345-348.
29. Lito P, Rosen N, Solit DB. Tumor adaptation and resistance to RAF inhibitors. Nat Med. 2013;19(11):1401-1409.
30. Chan EM, Shibue T, McFarland JM, et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature. 2019;568(7753):551-556.
31. Schmitt MW, Loeb LA, Salk JJ. The influence of subclonal resistance mutations on targeted cancer therapy. Nat Rev Clin Oncol. 2016;13(6):335-347.
32. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100-103. Martz CA, Ottina KA, Singleton KR, et al. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal. 2014;7(357):ra121.
33. Riaz M, Sieuwerts AM, Look MP, et al. High TIMP-1 mRNA expression is associated with adverse prognosis and gene expression patterns reflecting mesenchymal features of breast cancer. Breast Cancer Res Treat. 2014;148(3):535-546.
34. Pérez-Tomás R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem. 2006;13(16):1859-1876.

35. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253-265.
36. Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE. Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat. 2012;15(1-2):50-61.
37. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307-320.
38. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia. 2009;14(1):3-9. Yin H, Kauffman KJ, Anderson DG. Delivery technologies for genome editing. Nat Rev Drug Discov. 2017;16(6):387-399.
39. Wang Y, Song W, Huo M, et al. Drug penetration: barriers and solutions. J Pharm Sci. 2008;97(11):3980-3996.
40. Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1(5):16014.
41. Xu X, Saw PE, Tao W, Li Y, Ji X, Bhasin S, Liu Y, Ayyash D, Rasmussen J, Huo M, Shi J, Farokhzad OC. ROS-responsive polyprodrug nanoparticles for triggered drug delivery and effective cancer therapy. Adv Mater. 2017;29(33):1700141.
42. Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev. 2015;91:3-6.
43. Swaminathan SK, Roger E, Toti U, Niu L, Ohlfest JR, Panyam J. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release. 2013;171(3):280-287.
44. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278-287.
45. Patel SA, Minn AJ. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity. 2018;48(3):417-433.
46. Li J, Shaffer JM, Rangaraj D, et al. Systems pharmacology reveals the mechanistic landscape of mTOR inhibition in epidermal growth factor receptor- (EGFR-) driven lung cancer. Commun Biol. 2021;4(1):301.
47. Nalawade S, Chatterjee S, Chowdhury R. Pharmacokinetic considerations in special populations- pediatrics and geriatrics. J Pharm Bioallied Sci. 2016;8(4):266-277. Wu L, Qu X. Cancer biomarker detection: recent achievements and challenges. Chem Soc Rev. 2015;44(10):2963-2997.
48. Huang T, Alvarez A, Hu B. Long noncoding RNAs in Cancer: From bench to bedside. Adv Exp Med Biol. 2017;1008:199-223.
49. Liu F, Li X, Lu C, et al. Long non-coding RNA BCAR4 promotes chemo-resistance in human breast cancer cells by regulating miR-770-5p and MDR1. Genes Cells. 2020;25(4):210-222.
50. Xu H, Li Y, Chen H, et al. Long non-coding RNA LOC285194 confers resistance to chemotherapy in glioma cells by regulating miR-211-5p/DPYD axis. Front Oncol. 2020;10:442.
51. Zhang W, Du M, Wang T, et al. Long non-coding RNA LINC00162 promotes cell growth, migration, and invasion through regulating miR-485/BCL9 in breast cancer. Cancer Cell Int. 2020;20:78.
52. Zhou S, Jiang H, Li M, et al. Long non-coding RNA SNHG16 promotes the development of colorectal cancer by sponging miR-140-5p. Onco Targets Ther. 2019;12:1961-1970.
53. Chen Y, Li Z, Chen X, et al. Long non-coding RNA TTN-AS1 promotes the progression of colorectal cancer via miR-497-5p/FOXK1 axis. Cancer Cell Int. 2019;19:157.
54. Huang T, Liu HW, Chen JQ, Wang SH, Hao LQ, Liu M. Long noncoding RNA AB073614 regulates sorafenib resistance in hepatocellular carcinoma through miR-203-mediated downregulation of ATP-binding cassette subfamily G member 2. Asian Pac J Cancer Prev. 2015;16(13):5381-5387.
55. Chen P, Zhang J, Chu C, Chen M, Zhang L. LncRNA KCNQ1OT1 mediates pyroptosis in myocardial infarction by targeting the miR-9/CDK9 axis. Int J Cardiol. 2021;334:51-58.
56. Gao S, Wang P, Hua Y, Xi H, Meng Z, Liu T. Knockdown of long non-coding RNA LINC00173 promotes the radiosensitivity of osteosarcoma cells by miR-203a-3p/ATG12 axis. Cancer Manag Res. 2021;13:1677-1692. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219-234.
57. Chen KG, Sikic BI. Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res. 2012;18(7):1863-1869.

58. Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol. 2008;1(2):93-105.
59. Xu J, Liu Y, Wang J, et al. Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrin in xenografted nude mice. Cancer Biol Ther. 2011;11(2):121-130.
60. Yin L, Xu L, Zhao Y, et al. Co-delivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma. Mol Pharm. 2015;12(3):922-931.
61. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48-58. Zhang H, Wang J, Mao W, et al. Multidrug resistance reversal in cancer: Recent progress and perspectives. Pharmacol Res. 2020;151:104561.
62. Lu Y, Liu P, Wen W, et al. Lipid nanoparticle co-delivery of curcumin and doxorubicin for the reversal of multidrug resistance in breast cancer cells. Colloids Surf B Biointerfaces. 2018;169:15-22.
63. Kathawala RJ, Gupta P, Ashby CR Jr, Chen ZS. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat. 2015;18:1-17.